The US company's lead product candidate is vadadustat. It is part of a new class of investigational agents called oral hypoxia-inducible factor prolyl hydroxylase inhibitors.

Within Japan, Vafseo (vadadustat) is approved as a treatment for anemia due to CKD in both dialysis-dependent and non-dialysis dependent adult patients.